$ 450.0
Quantity: 50 MG
In stock (can be backordered)
Description
Product name: gp100 (210M) peptide
Catalog#: 1401033
Organism:
Synonyms: Modified gp100 peptide (210M),
CAS NO.:
Sequence: IMDQVPFSV
Modifications:
M.W:1035.22
M.F.:C47H74N10O14S1
Purity: 95% by HPLC
Counter ion: Trifluoacetate
Format: Lyophilized powder
Description: A peptide derived from gp100 (a lineage-restricted antigen) has been synthesized in a mutated (heteroclitic) form for the purpose of enhancing HLA-A2.1 binding. This peptide, gp100:209-217(210M) binds with a higher affinity to HLA-A2 than the native peptide and induces better T-cell stimulation in vitro and in vivo. Initial clinical trials at the National Cancer Institute (NCI) with 210M demonstrated induction in peripheral blood of peptide- and tumor-specific cytotoxic T-lymphocyte responses in 10 of 11 patients with HLA-A2.1–positive melanoma, although no definitive antitumor activity was observed.
Uniprot ID:
Usage: For Scientific Research Use Only, Not for Human Use.
